S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:ARNA

Arena Pharmaceuticals - ARNA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$99.99
$99.99
50-Day Range
$93.13
$99.99
52-Week Range
$45.50
$100.00
Volume
107 shs
Average Volume
1.56 million shs
Market Capitalization
$6.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.00

Arena Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.0% Upside
$100.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.32) to ($6.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.24 out of 5 stars

Medical Sector

1026th out of 1,055 stocks

Pharmaceutical Preparations Industry

501st out of 519 stocks


ARNA stock logo

About Arena Pharmaceuticals (NASDAQ:ARNA) Stock

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Receive ARNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARNA Stock News Headlines

Obesity Drugs: The Road to Perdition
Pfizer to Buy Global Blood Therapeutics
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
7 Biotech Stocks With Key Catalysts in March
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Arena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31
SFO opens criminal probe into collapse of Arena Television
Expert Ratings For Arena Pharmaceuticals
See More Headlines

Receive ARNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARNA Company Calendar

Last Earnings
11/04/2021
Today
1/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ARNA
CUSIP
04004710
Employees
448
Year Founded
1977

Price Target and Rating

Average Stock Price Forecast
$100.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$100.00
Forecasted Upside/Downside
+0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-616,430,000.00
Pretax Margin
-1,141,542.63%

Debt

Sales & Book Value

Annual Sales
$50,000.00
Price / Sales
123,305.67
Book Value
$10.94 per share

Miscellaneous

Free Float
60,173,000
Market Cap
$6.17 billion
Optionable
Optionable
Beta
0.55

Social Links


Key Executives

  • Mr. Amit D. Munshi M.B.A. (Age 54)
    Pres & CEO
    Comp: $1.22M
  • Ms. Laurie D. Stelzer (Age 54)
    Exec. VP & CFO
    Comp: $630.76k
  • Mr. Vincent E. AurentzMr. Vincent E. Aurentz (Age 54)
    Exec. VP & Chief Bus. Officer
    Comp: $692.82k
  • Dr. Christopher H. Cabell FACC
    M.D., MHS, Advisor
  • Mr. Robert LisickiMr. Robert Lisicki (Age 54)
    Exec. VP & Chief Commercial Officer
    Comp: $686.63k
  • Dr. Douglas A. Bakan Ph.D.
    Exec. VP of Technical Operations
  • Dr. Lamine Mbow Ph.D.
    Sr. VP & Chief Scientific Officer
  • Megan E. Knight
    Director of Investor Relations
  • Patrick Malloy
    VP of Investor Relations & Corp. Communications
  • Mr. Michael E. Paolucci (Age 62)
    Exec. VP of HR













ARNA Stock - Frequently Asked Questions

Should I buy or sell Arena Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ARNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares.
View ARNA analyst ratings
or view top-rated stocks.

What is Arena Pharmaceuticals' stock price forecast for 2023?

1 brokerages have issued 12-month target prices for Arena Pharmaceuticals' shares. Their ARNA share price forecasts range from $100.00 to $100.00. On average, they anticipate the company's stock price to reach $100.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for ARNA
or view top-rated stocks among Wall Street analysts.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. During the same period in the previous year, the company posted ($1.69) EPS.

When did Arena Pharmaceuticals' stock split?

Arena Pharmaceuticals's stock reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among the company's employees.

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $99.99.

How much money does Arena Pharmaceuticals make?

Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. The biopharmaceutical company earns $-616,430,000.00 in net income (profit) each year or ($10.13) on an earnings per share basis.

How many employees does Arena Pharmaceuticals have?

The company employs 448 workers across the globe.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.arenapharm.com. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at ir@arenapharm.com, or via fax at 858-453-7210.

This page (NASDAQ:ARNA) was last updated on 1/28/2023 by MarketBeat.com Staff